Aligos Therapeutics Inc Ordinary Shares ALGS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALGS is a good fit for your portfolio.
News
-
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
-
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
-
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
-
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
-
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
-
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
-
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
-
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
Trading Information
- Previous Close Price
- $0.83
- Day Range
- $0.78–0.83
- 52-Week Range
- $0.54–1.38
- Bid/Ask
- $0.79 / $0.80
- Market Cap
- $60.52 Mil
- Volume/Avg
- 52,276 / 422,416
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.43
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 66
- Website
- https://www.aligos.com
Valuation
Metric
|
ALGS
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.68 |
Price/Sales | 3.43 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
ALGS
|
---|---|
Quick Ratio | 5.68 |
Current Ratio | 5.90 |
Interest Coverage | — |
Quick Ratio
ALGS
Profitability
Metric
|
ALGS
|
---|---|
Return on Assets (Normalized) | −61.60% |
Return on Equity (Normalized) | −93.03% |
Return on Invested Capital (Normalized) | −82.11% |
Return on Assets
ALGS
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jhsmtqtzcj | Lrv | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mflbvvpgv | Snhgzql | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vznqltxw | Ktnfl | $99.5 Bil | |
MRNA
| Moderna Inc | Dwhxmylhr | Zwn | $38.8 Bil | |
ARGX
| argenx SE ADR | Hgqpdqyfx | Xxdd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Vycbtlpzh | Wjk | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Shmkjksl | Szngfn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vqhnpyqh | Vrlgp | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ywkqfbkbp | Zsvpnmn | $12.5 Bil | |
INCY
| Incyte Corp | Fjbchzfj | Gzpbzd | $11.6 Bil |